Amgen Inc. Stock Performance
Amgen Inc. shares closed at $414.87, reflecting a daily decline of approximately 2.50% per SID market data. Despite the single-session pullback, the stock has demonstrated consistent positive momentum across multiple timeframes, gaining 4.13% over the past month, 12.12% over three months, and 22.91% over the trailing twelve months. The current price sits above both key moving averages, trading at a premium to the 50-day moving average of $411.34 and well above the 200-day moving average of $371.60, indicating a sustained uptrend. The 14-day relative strength index registers at 63.0, suggesting moderate bullish momentum without entering overbought territory. Amgen's beta of 0.472 according to SID market data underscores the stock's low-volatility profile relative to the broader market. Average daily trading volume stands at approximately 2.89 million shares, supporting adequate liquidity for institutional participation. The company's market capitalization currently totals approximately $209.2 billion.
Amgen Inc. Valuation Analysis
Amgen Inc. currently trades at a price-to-earnings ratio of 27.13, reflecting a premium valuation relative to historical healthcare sector norms, according to SID market data. The PEG ratio stands at 2.72, suggesting the stock's earnings growth rate does not fully justify its current P/E multiple at present levels. The price-to-book ratio registers at 24.16, a notably elevated figure that reflects Amgen's significant intangible asset base and goodwill from prior acquisitions, per SEC filings. From an income perspective, the company offers a dividend yield of approximately 2.49%, providing a meaningful income component for shareholders and positioning Amgen among the higher-yielding large-cap biotechnology names. Within the broader healthcare sector, these valuation metrics indicate that the market is pricing in expectations for continued revenue expansion from Amgen's diversified drug portfolio. Investors appear to be assigning a growth premium despite the stock's relatively defensive beta characteristics.
Smart Money Activity for AMGN
Amgen Inc. registers a composite smart money score of 48 out of 100, reflecting a neutral overall signal according to SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained interest from large asset managers and pension funds as documented in 13F institutional filings. In contrast, insider activity scores a modest 8.6 out of 25, with SEC Form 4 filings revealing 15 insider transactions over the past 90 days, comprising 9 purchases and 6 sales. The slight skew toward insider buying suggests measured confidence among company executives, though the overall insider score remains subdued. Dark pool activity registers at 8.5 out of 25, indicating limited off-exchange institutional accumulation at current price levels. Congressional trading activity scores 5.9 out of 25, reflecting minimal recent legislative interest. The divergence between maximum institutional conviction and below-average scores across other smart money categories produces the neutral composite reading, suggesting no dominant directional bias from sophisticated market participants.
Amgen Inc. Earnings Outlook
Amgen Inc. has delivered three consecutive quarters of earnings beats, demonstrating consistent operational execution according to company earnings reports. In the most recent reported quarter ending February 2026, the company posted earnings per share of $5.29, surpassing the consensus estimate of $4.75 by $0.54. The following quarter saw EPS of $5.15 against estimates of $4.76, a positive surprise of $0.39, while the August 2026 quarter recorded the largest beat at $6.29 versus the $5.60 estimate, a $0.69 upside surprise. The pattern of accelerating beat magnitudes suggests strengthening financial performance across Amgen's portfolio. Looking ahead, analyst estimates project EPS of $5.76 for the upcoming quarter with results expected on November 3, 2026. The consensus forecast represents a sequential decline from the prior quarter's $6.29, though it exceeds the year-ago comparable period. Continued execution above estimates could support further multiple expansion.
Wall Street Analyst Ratings for AMGN
Recent Wall Street coverage of Amgen Inc. reflects a mixed but modestly constructive consensus, according to SID consensus data. In the most recent ratings activity, UBS reiterated its Buy rating on October 9, 2026, while RBC Capital maintained an Outperform designation on October 8, 2026, representing the two most bullish stances among recent coverage updates. Counterbalancing these positive views, Cantor Fitzgerald reiterated a Neutral rating on October 8, 2026, and Truist Securities maintained a Hold rating on October 7, 2026, per Wall Street analyst reports. Morgan Stanley also reiterated its Equal-Weight rating on October 7, 2026, aligning with the cautious camp. Notably, none of the five most recent analyst actions involved rating changes, with all firms maintaining their prior designations. This stability in ratings suggests the analyst community has largely priced in Amgen's current fundamentals, with the split between two bullish and three neutral ratings reflecting a balanced view on the stock's risk-reward profile at current levels near $414.87.
